Advanced Oncotherapy (AVO) strengthens its board – Daily Telegraph

From Daily Telegraph – StockMarket Wire Advanced Oncotherapy has appointed Dr Nick Plowman as a non-executive director with immediate effect. Plowman is senior clinical oncologist at St Bartholomew’s Hospital and the Hospital for Sick Children at Great Ormond Street in London. Executive chairman Michael Sinclair said: “Dr Plowman has been a welcome source of expert […]

Brand CEO Alan Green talks Advanced Oncotherapy (AVO), Conviviality (CVR), Safestyle (SFE) & Asiamet (ARS) on VOX Markets podcast

<iframe class="wp-embedded-content" sandbox="allow-scripts" security="restricted" width="480" height="300" frameborder="0" scrolling="no" src="//embeds.audioboom slimming pills that work.com/posts/5592554-707-zenith-energy-zen-the-peoples-operator-tpop-plus-russ-mould-alan-green/embed/v4?eid=AQAAAO2xnVjqVVUA#?secret=PUxVeJDHHI” data-secret=”PUxVeJDHHI” title=”audioBoom player”> Brand CEO Alan Green discusses Advanced Oncotherapy (AVO), Conviviality (CVR), Safestyle (SFE) & Asiamet (ARS) with Justin Waite on the VOX Markets podcast. The interview starts at 37 minutes 7 seconds.

Advanced Oncotherapy (AVO) – Appoints Dr Nick Plowman as Non-Executive Director

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Dr Nick Plowman, Senior Clinical Oncologist at St Bartholomew’s Hospital (“Barts”) and the Hospital for Sick Children at Great Ormond Street (“GOSH”) in London, as a Non-Executive Director with immediate effect. Dr Nick Plowman is the UK’s […]

Advanced Oncotherapy (AVO) – Significant Shareholder

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on 7 February 2017 that Dr Nick Plowman, Chairman of the Company’s medical advisory board, became a significant shareholder on 6 June 2016 and, following subsequent share purchases, currently holds 2,636,799 ordinary shares of 25 pence each in […]

Advanced Oncotherapy (AVO) – Sinophi update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has come to an agreement with Sinophi Healthcare Limited to terminate the purchase orders announced on 25 March 2015 and 21 October 2015. In addition, both parties have reached an agreement to terminate the distribution agreement also announced […]

Beaufort Securities view on Advanced Oncotherapy (AVO)

Beaufort Securities view on Advanced Oncotherapy (AVO). It always comes as a surprise when the market reacts violently to some news item whose impact was considered already to be priced-in. Yesterday’s announcement told shareholders nothing new. Back in November, AVO detailed the fact that Sinophi was no longer to proceed with the installation of LIGHT […]

Advanced Oncotherapy (AVO) – Appointment of Non-Executive Directors

  Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Professor Steve Myers OBE and Mr Hans von Celsing as Non-Executive Directors with immediate effect. In addition, Mr von Celsing will become Senior Independent Non-Executive Director. Professor Myers’ appointment follows the announcement of the Company’s intention to […]

Advanced Oncotherapy (AVO) – Sinophi Update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment announces that on 23 January 2017, the Company was informed by Sinophi Healthcare Limited (“Sinophi”) that it wished to terminate the purchase orders announced on 25 March 2015 and 21 October 2015. Advanced Oncotherapy is firmly of the view that Sinophi has no […]

Advanced Oncotherapy (AVO) Non-dilutive financing plan update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, in September 2016, it commenced discussions concerning a proposal it had received from a potential strategic partner that involves, inter alia, non-dilutive financing arrangements, which were mentioned in the announcement of 30 September 2016. Discussions with this potential partner are […]